RemeGen (HKG:9995) will present the results of its phase 3 study for its telitacicept for generalized myasthenia gravis, according to a Monday filing with the Hong Kong bourse.

The company was chosen as the latest breakthrough study for the heavyweight oral presentation of the 2025 American Academy of Neurology Annual Meeting, the filing said.

The presentation will focus on the efficacy and safety of patients with the autoimmune disease, which destroys communication between nerves and muscles resulting in weak skeletal muscles, the filing said.